Celgene revenue up 16 pct on demand for Revlimid
Jan 26 (Reuters) - U.S. biotechnology company Celgene Corp on Thursday, reported a 16 percent jump in quarterly revenue, helped by demand for its flagship multiple myeloma drug, Revlimid. [Source]
Publication Date:Origin: reuters.com
Category: hotStocksNews
Topics: Revlimid, demand, Celgene, myeloma drug, multiple, flagship, helped, quarterly revenue, percent, reported, company, biotechnology, (Reuters), revenue
Source: http://feeds.reuters.com/~r/reuters/hotStocksNews/~3/fmEPQZ7zvg4/celgene-results-idUSL4N1FG3HM